NCT02759250View on ClinicalTrials.gov

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 25, 2018

Study Completion Date

June 30, 2018

Conditions
Cancer
Interventions
DRUG

ARGX-110

Trial Locations (1)

Unknown

UZG - Universitair Ziekenhuis Gent, Ghent

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT02759250 - A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) | Biotech Hunter | Biotech Hunter